Drugs / IL-2 pre-treated CD19 cells
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT02992834 Comparator | Dec 2016 → Aug 2020 | B-cell non-Hodgkin lymphoma | jiangjingting | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IL-2 pre-treated CD19 cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02992834 ↗ |
| Modality | Cell therapy | “TCRζ chimeric antigen receptor-T cell” NCT02992834 ↗ |